IL28B polymorphism and the control of hepatitis C virus infection : ready for clinical use ?
| Journal | Volume 74 - 2011 |
| Issue | Fasc.2 - Case series |
| Author(s) | Hans Orlent, Hendrik Reynaert, Stefan Bourgeois, Vinciane Dideberg, Michael Adler, Isabelle Colle, Stéphane De Maeght, Wim Laleman, Peter Michielsen, Christophe Moreno, Jean-Pierre Mulkay, Peter Stärkel, Jean Delwaide |
| Full article |
 VIEW FREE PDF |
| (1)Department of Gastroenterology and Hepatology, AZ St. Jan AV, Bruges, Belgium; (2)Department of Gastroenterology, UZ Brussel, Brussels, Belgium; (3) Department of Gastroenterology, AZ Stuivenberg, Antwerp, Belgium ; (4) Department of Genetics, CHU Sart Tilman, University of Liège, Liège, Belgium ; (5) Department of Gastroenterology and Hepatopancreatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium ; (6) Department of Hepatology and Gastroenterology, Ghent University Hospital, Ghent, Belgium ; (7) Service d'Hépato-Gastroentérologie, Hôpital de Jolimont, Haine-Saint-Paul, Belgium ; (8) Department of Hepatology, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium ; (9) Division of Hepatogastroenterology, University Hospital Antwerp, Belgium ; (10) Department of Hepatogastroenterology, CHU Saint-Pierre, Brussels, Belgium ; (11) Service d'Hépatologie, Cliniques Universitaires St-Luc UCL, Woluwe, Belgium ; (12) Department of Gastroenterology, CHU Sart Tilman, University of Liège, Liège, Belgium. |
|
Polymorphisms in the region of the interleukin-28B (IL28B) gene have recently been associated with spontaneous and treatment induced clearance of hepatitis C virus infection. The specific mechanisms of how IL28B polymorphisms affect HCV suppression remain unknown. It is a matter of ongoing debate how to incorpo- rate the IL28B data into the current treatment algorithms with pegylated interferon-alpha and ribavirin. The eventual role of the IL28B genotype in new therapeutic regimes with direct antiviral agents needs to be explored in the ongoing and future clinical studies with these agents. (Acta gastroenterol. belg., 2011, 74, 317- 322). |
|
© Acta Gastro-Enterologica Belgica. PMID 21861317 |
